Stem cells for drug screening

Journal of Cardiovascular Pharmacology

Volumn 58, Issue 3, 2011, Pages 240-245

  Laposa, Rebecca R ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

HESC; hiPSC; hPSC; human embryonic stem cells; human induced pluripotent stem cell; human pluripotent stem cell; iCM; induced cardiomyocyte

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; ADRENALIN; ADRENERGIC RECEPTOR STIMULATING AGENT; AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIX 01294; CALCIUM CHANNEL BLOCKING AGENT; CARBACHOL; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHROMANOL 293B; DILTIAZEM; DOXAZOSIN; DOXORUBICIN; FLECAINIDE; IMATINIB; ISOPRENALINE; MEXILETINE; MUSCARINIC AGENT; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PHENYLEPHRINE; PROCAINAMIDE; PROPRANOLOL; QUINIDINE; SODIUM CHANNEL BLOCKING AGENT; STAUROSPORINE; TERFENADINE; TETRODOTOXIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALINOMYCIN; VERAPAMIL;

CARDIOTOXICITY; CELL DIFFERENTIATION; DNA METHYLATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SCREENING; EMBRYONIC STEM CELL; EPIGENETICS; GENE EXPRESSION; GENE MUTATION; HEART MUSCLE CELL; HUMAN; INNER CELL MASS; NUCLEAR REPROGRAMMING; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REVIEW; STEM CELL; VIRAL GENE DELIVERY SYSTEM;

CARDIOVASCULAR AGENTS; DRUG EVALUATION, PRECLINICAL; EMBRYONIC STEM CELLS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MYOCYTES, CARDIAC;

EID: 80052779178     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31821823f5     Document Type: Review

References (51)

1. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov. 2004;3:711-715. (Pubitemid 39173511)
2. Fermini B, Fossa AA. The impact of drug-induced QT interval prolongation on drug discovery and development. Nat Rev Drug Discov. 2003;2:439-447. (Pubitemid 37361725)
3. Kettenhofen R, Bohlen H. Preclinical assessment ofcardiac toxicity. Drug Discov Today. 2008;13:702-707.
4. Yang L, Soonpaa MH, Adler ED, et al. Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population. Nature. 2008;453:524-528. (Pubitemid 351733312)
5. Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts. Science. 1998;282:1145-1147. (Pubitemid 28516247)
6. Itskovitz-Eldor J, Schuldiner M, Karsenti D, et al. Differentiation of human embryonic stem cells into embryoid bodies compromising the three embryonic germ layers. Mol Med. 2000;6:88-95.
7. Nussbaum J, Minami E, Laflamme MA, et al. Transplantation of undifferentiated murine embryonic stem cells in the heart: teratoma formation and immune response. FASEB J. 2007;21:1345-1357. (Pubitemid 46684837)
8. Laflamme MA, Chen KY, Naumova AV, et al. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat Biotechnol. 2007;25:1015-1024. (Pubitemid 47517637)
9. van Laake LW, Passier R, Doevendans PA, et al. Human embryonic stem cell-derived cardiomyocytes and cardiac repair in rodents. Circ Res. 2008; 102:1008-1010. (Pubitemid 351667854)
10. Doetschman TC, Eistetter H, Katz M, et al. The in vitro development of blastocyst-derived embryonic stem cell lines: formation ofvisceral yolk sac, blood islands and myocardium. JEmbryol Exp Morphol. 1985;87:27-45. (Pubitemid 15029925)
11. Murry CE, Keller G. Differentiation of embryonic stem cells to clinically relevant populations: lessons from embryonic development. Cell. 2008; 132:661-680. (Pubitemid 351260059)
12. Braam SR, Tertoolen L, van de Stoipe A, et al. Prediction ofdrug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes. Stem Cell Res. 2010;4:107-116.
13. Kattman SJ, Huber TL, Keller GM. Multipotent flk-1+ cardiovascular progenitor cells give rise to the cardiomyocyte, endothelial, and vascular smooth muscle lineages. Dev Cell. 2006;11:723-732. (Pubitemid 44644969)
14. Mummery C. Sorting cardiomyocytes: a simple solution after all? Nat Meth. 2010;7:40-42.
15. Hattori F, Chen H, Yamashita H, et al. Nongenetic method for purifying stem cell-derived cardiomyocytes. Nat Meth. 2010;7:61-66.
16. Takahashi K, Yamanaka S. Induction ofpluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126: 663-676. (Pubitemid 44233629)
17. Takahashi K, Tanabe K, Ohnuki M, et al. Induction ofpluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861-872. (Pubitemid 350138099)
18. Huangfu D, et al. Induction ofpluripotent stem cells by defined factors is greatly improved by small-molecule compounds. Nat Biotechnol. 2008; 26:795-797. (Pubitemid 351961456)
19. Shi Y Desponts C, Do JT, et al. Induction ofpluripotent stem cells from mouse embryonic fibroblasts by Oct4 and Klf4 with small-molecule compounds. Cell Stem Cell. 2008;3:568-574.
20. Li W, Wei W, Zhu S, et al. Generation of rat and human induced pluripotent stem cells by combining genetic reprogramming and chemical inhibitors. Cell Stem Cell. 2009;4:16-19.
21. Shi Y Do JT, Desponts C, et al. A combined chemical and genetic approach for the generation of induced pluripotent stem cells. Cell Stem Cell. 2008;2:525-528. (Pubitemid 351729222)
22. Huangfu D, Osafune K, Maehr R, et al. Induction ofpluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nat Biotechnol. 2008;26:1269-1275.
23. Yuan X, Wan H, Zhao X, et al. Combined chemical treatment enables Oct4-induced reprogramming from mouse embryonic fibroblasts. Stem Cells. In press.
24. Woltjen K, Michael IP, Mohseni P, et al. Piggy Bac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature. 2009; 458:766-770.
25. Gupta MK, Illich DJ, Gaarz A, et al. Global transcriptional profiles of beating clusters derived from human induced pluripotent stem cells and embryonic stem cells are highly similar. BMCDev Biol. 2010;10:98.
26. Gai H, Leung EL, Costantino PD, et al. Generation and characterization of functional cardiomyocytes using induced pluripotent stem cells derived fromhuman fibroblasts. Cell Biol Int. 2009;33:1184-1193.
27. Yokoo N, Baba S, Kaichi S, et al. The effects of cardioactive drugs on cardiomyocytes derived from human induced pluripotent stem cells. Biochem Biophys Res Commun. 2009;387:482-488.
28. Narsinh KH, Sun N, Sanchez-Freire V, et al. Single cell transcriptional profiling reveals heterogeneity of human induced pluripotent stem cells. J Clin Invest. 2011.
29. Yoshida Y Yamanaka S. i PS cells: a source ofcardiac regeneration. JMol Cell Cardiol. 2010.
30. Yamanaka S. Patient-specific pluripotent stem cells become even more accessible. Cell Stem Cell. 2010;7:1-2.
31. Moretti A, Bellin M, Welling A, et al. Patient-specific induced pluripotent stem-cell models for long-QT syndrome. NEngl JMed. 2010;363:1397-1409.
32. Carvajal-Vergara X, Sevilla A, D'Souza SL, et al. Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. Nature. 2010;465:808-812.
33. Zhou Q, Brown J, Kanarek A, et al. In vivo reprogramming of adult pancreatic exocrine cells to beta-cells. Nature. 2008;455:627-632.
34. Vierbuchen T, Ostermeier A, Pang ZP, et al. Direct conversion of fibroblasts to functional neurons by defined factors. Nature. 2010;463: 1035-1041.
35. Szabo E, Rampalli S, Risueno RM, et al. Direct conversion of human fibroblasts to multilineage blood progenitors. Nature. 2010.
36. Ieda M, Fu JD, Delgado-Olguin P, et al. Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell. 2010; 142:375-386.
37. Denning C, Anderson D. Cardiomyocytes from human embryonic stem cells as predictors of cardiotoxicity. Drug Discov Today. 2008;5: 223-232.
38. Dick E, Rajamohan D, Ronksley J, et al. Evaluating the utility of cardiomyocytes from human pluripotent stem cells for drug screening. Biochem Soc Trans. 2010;38:1037-1045.
39. Mummery C, Ward-van-Oostwaard D, Doevendans P, et al. Differenti-ation of human embryonic stem cells to cardiomyocytes: role of coculture with visceral endoderm-like cells. Circulation. 2003;107:2733-2740. (Pubitemid 36667249)
40. Passier R, van Laake LW, Mummery CL. Stem-cell-based therapy and lessons from the heart. Nature. 2008;453:322-329. (Pubitemid 351693138)
41. Satin J, Kehat I, Caspi O, et al. Mechanism of spontaneous excitability in human embryonic stem cell derivedcardiomyocytes. JPhysiol. 2004;559: 479-496. (Pubitemid 39263813)
42. Schenke-Layland K, Mac Lellan WR. Induced pluripotent stem cells: it's like deja vu all over again. Circulation. 2009;120:1462-1464.
43. Xu C, Police S, Rao N, et al. Characterization and enrichment of cardiomyocytes derived from human embryonic stem cells. Circ Res. 2002;91:501-508.
44. Zwi L, Caspi O, Arbei G, et al. Cardiomyocyte differentiation ofhuman induced pluripotent stem cells. Circulation. 2009;120:1513-1523.
45. Tanaka T, Tohyama S, Murata M, et al. In vitro pharmacologic testing using human induced pluripotent stem cell-derived cardiomyocytes. Biochem Biophys Res Commun. 2009;385:497-502.
46. Zhang J, Wilson GF, Soerens AG, et al. Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ Res. 2009;104: e30-e41.
47. Anson BD, Kolaja KL, Kamp TJ. Opportunites for use ofhuman i PS cells in predictive toxicology. Clin Pharmacol Ther. In press.
48. Rosen MR. Consequences of the Sicilian Gambit Eur Heart J. 1995; 16(suppl G):32-36.
49. Liang H, Matzkies M, Schunkert H, et al. Human and murine embryonic stem cell-derived cardiomyocytes serve together as a valuable model for drug safety screening. Cell Physiol Biochem. 2010;25:459-466.
50. Caspi O, Itzhaki I, Kehat I, et al. In vitro electrophysiological drug testing using human embryonic stem cell derived cardiomyocytes. Stem Cells Dev. 2009;18:161-172.
51. Yasuda K On-chip Cellomics technology for drug screening system using cardiomyocyte cells from human stem cell. Yakugaku Zasshi. 2010;130: 545-557.